FDA Feedback and Capital Raise
Invivyd received feedback from the U.S. FDA to develop the vaccine alternative antibody, VYD2311, and successfully raised approximately $87 million in capital to fund intended studies and expand the commercial organization.
Revenue Growth
Invivyd reported a revenue increase of 11% quarter-on-quarter and 41% year-over-year, reflecting efforts in driving market awareness.
Expansion in GPO Sites
The company has over 15,000 contracted GPO sites and more than 1,200 sites offering infusion, with 76% of accounts reordering.
Broad Commercial Opportunity
The company plans to provide a widely available option to prevent COVID for most Americans, with a near-term commercial opportunity, as last year's U.S. COVID vaccine sales totaled $3.8 billion.